Loading patent…
OwnerPatricia A. Billing-Medel, Maurice Cohen +9inventors
InventorsPatricia A. Billing-Medel, Maurice Cohen, Tracey L. Colpitts, Paula N. Friedman, Julian Gordon, Edward N. Granados, Steven C. Hodges, Michael R. Klass, Jon D. Kratochvil, John C. Russell, Stephen D. Stroupe
Estimating the term…
A set of contiguous and partially overlapping cDNA sequences and polypeptides encoded thereby, designated as BS325 and transcribed from breast tissue, is described. These sequences are useful for the detecting, diagnosing, staging, monitoring, prognosticating, in vivo imaging, preventing or treating, or determining the predisposition of an individual to diseases and conditions of the breast, such as breast cancer. Also provided are antibodies which specifically bind to BS325-encoded polypeptide or protein, and agonists or inhibitors which prevent action of the tissue-specific BS325 polypeptide, which molecules are useful for the therapeutic treatment of breast diseases, tumors or metastases
A method of detecting the presence of a target BS325 polynucleotide in a test sample, said method comprising:
A method for detecting BS325 mRNA in a test sample, said method comprising:
A method of detecting a target BS325 polynucleotide in a test sample suspected of containing said target polynucleotide, comprising:
A test kit useful for detecting BS325 polynucleotide in a test sample, said test kit comprising a container containing at least one BS325 polynucleotide having at least 50% identity with a sequence selected from the group consisting SEQUENCE ID NOS 1-10, and fragments or complements thereof.
A purified polynucleotide derived from a BS325 nucleic acid molecule, wherein said polynucleotide has at least 50% identity with a sequence selected from the group consisting of SEQUENCE ID NOS 1-10, and fragments or complements thereof.
A recombinant expression system comprising a nucleic acid sequence that includes an open reading frame derived from a BS325 polynucleotide, wherein said open reading frame is operably linked to a control sequence compatible with a desired host, and said nucleic acid sequence has at least 50% identity with a sequence selected from the group consisting of SEQUENCE ID NOS 1-10, and fragments or complements thereof.
A BS325 polypeptide having at least 50% identity with an amino acid sequence selected from the group consisting of SEQUENCE ID NO 19, SEQUENCE ID NO 20, SEQUENCE ID NO 21, SEQUENCE ID NO 22, SEQUENCE ID NO 23, and fragments thereof.
A specific binding molecule that binds to at least one BS325 epitope, wherein said BS325 epitope is derived from an amino acid sequence having at least 50% identity with an amino acid sequence selected from the group consisting of SEQUENCE ID NO 19, SEQUENCE ID NO 20, SEQUENCE ID NO 21, SEQUENCE ID NO 22, SEQUENCE ID NO 23, and fragments thereof.
A test kit for determining the presence of BS325 antigen or anti-BS325 antibody in a test sample, said kit comprising a container containing a BS325 polypeptide having at least 50% identity with an amino acid sequence selected from the group consisting of SEQUENCE ID NO 19, SEQUENCE ID NO 20, SEQUENCE ID NO 21, SEQUENCE ID NO 22, SEQUENCE ID NO 23, and fragments thereof.
A test kit for determining the presence of BS325 antigen in a test sample, said kit comprising a container containing a specific binding molecule which binds to a BS325 antigen having at least one BS325 epitope.
A method for producing a polypeptide comprising at least one BS325 epitope, said method comprising incubating host cells that have been transfected with an expression vector containing a polynucleotide sequence encoding a polypeptide, wherein said polypeptide comprises an amino acid sequence having at least 50% identity with an amino acid sequence selected from the group consisting of SEQUENCE ID NO 19, SEQUENCE ID NO 20, SEQUENCE ID NO 21, SEQUENCE ID NO 22, SEQUENCE ID NO 23, and fragments thereof.
A method for detecting BS325 antigen in a test sample suspected of containing said BS325 antigen, comprising:
A method for detecting the presence of antibodies specific for a BS325 antigen in a test sample suspected of containing such antibodies, said method comprising:
A cell transfected with a nucleic acid sequence encoding at least one BS325 epitope, wherein said nucleic acid sequence is selected from the group consisting of SEQUENCE ID NOS 1-10, and fragments or complements thereof.
A method for producing antibodies that specifically bind to BS325 antigen, comprising administering to an individual an isolated immunogenic polypeptide or fragment thereof in an amount sufficient to elicit an immune response, wherein said immunogenic polypeptide comprises at least one BS325 epitope and has at least 50% identity with a sequence selected from the group consisting of SEQUENCE ID NO 19, SEQUENCE ID NO 20, SEQUENCE ID NO 21, SEQUENCE ID NO 22, SEQUENCE ID NO 23, and fragments thereof.
A method for producing antibodies that specifically hind to BS325 antigen, comprising administering to an individual a plasmid comprising a sequence that encodes at least one BS325 epitope derived from a polypeptide having an amino acid sequence selected from the group consisting of SEQUENCE ID NO 19, SEQUENCE ID NO 20, SEQUENCE ID NO 21, SEQUENCE ID NO 22, SEQUENCE ID NO 23, and fragments thereof.
Dependencies are inferred from the claim text.